ImmueMed
Contact Us
KO
Company
Company Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Notice
Financial Information
Investment Inquiry
Company
Company Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Notice
Financial Information
Investment Inquiry
Overall Menu
Company
Company
Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Investment
Information
Notice
Financial Information
Investment Inquiry
Press Release | ImmuneMed
Press Release
Home
Company News
Company
R & D
Company News
Investment Information
Publicity
Publicity
Press Release
Video Clip
[Journal of Clinical Medicine] COVID-19 Phase 2 Clinical Study Results
Writer
|
ImmuneMed
Views
|
7586
Date
|
2022-05-26
Prev 및 Next
Prev
[Heliyon] hzVSF inhibits hepatitis B virus infection by targeting viral cell entry
2022-05-26
Next
[Press Release] ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate
development of the treatment
2021-01-08